LIPOSYN 10%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPOSYN 10% is an intravenous lipid emulsion approved in 1979 for parenteral nutrition support. The product provides essential fatty acids and calories to patients unable to receive oral or enteral nutrition. It functions as a nutritional substrate rather than a pharmacologically active agent.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a mature brand with declining team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIPOSYN 10% offers limited growth trajectory and career acceleration opportunities due to its LOE-approaching status and minimal job-linked roles. Career value is concentrated in operational excellence, regulatory compliance, and defending market share against erosion rather than innovation or expansion.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on LIPOSYN 10% at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.